Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase

Uffe H Olesen; Jakob Geert Petersen; Antje Garten; Wieland Kiess; Jun Yoshino; Shin-Ichiro Imai; Mette K Christensen; Peter Fristrup; Annemette V Thougaard; Fredrik Björkling; Peter Boie Lind Jensen; Søren J Nielsen; Maxwell Sehested

doi:10.1186/1471-2407-10-677

Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase

Uffe H Olesen, Jakob Geert Petersen, Antje Garten, Wieland Kiess, Jun Yoshino, Shin-Ichiro Imai, Mette K Christensen, Peter Fristrup, Annemette V Thougaard, Fredrik Björkling, Peter Boie Lind Jensen, Søren J Nielsen, Maxwell Sehested

42 Citations (Scopus)

Abstract

Inhibitors of nicotinamide phosphoribosyltransferase (NAMPT) are promising cancer drugs currently in clinical trials in oncology, including APO866, CHS-828 and the CHS-828 prodrug EB1627/GMX1777, but cancer cell resistance to these drugs has not been studied in detail.

Original language	English
Journal	B M C Cancer
Volume	10
Pages (from-to)	677
ISSN	1471-2407
DOIs	https://doi.org/10.1186/1471-2407-10-677
Publication status	Published - 1 Jan 2010

Access to Document

10.1186/1471-2407-10-677

Cite this

Olesen, U. H., Petersen, J. G., Garten, A., Kiess, W., Yoshino, J., Imai, S-I., Christensen, M. K., Fristrup, P., Thougaard, A. V., Björkling, F., Jensen, P. B. L., Nielsen, S. J., & Sehested, M. (2010). Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase. B M C Cancer, 10, 677. https://doi.org/10.1186/1471-2407-10-677

Olesen, UH, Petersen, JG, Garten, A, Kiess, W, Yoshino, J, Imai, S-I, Christensen, MK, Fristrup, P, Thougaard, AV, Björkling, F, Jensen, PBL, Nielsen, SJ & Sehested, M 2010, 'Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase', B M C Cancer, vol. 10, pp. 677. https://doi.org/10.1186/1471-2407-10-677

@article{b335c6599e144d37a42f45b32dc1aa57,

title = "Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase",

abstract = "Inhibitors of nicotinamide phosphoribosyltransferase (NAMPT) are promising cancer drugs currently in clinical trials in oncology, including APO866, CHS-828 and the CHS-828 prodrug EB1627/GMX1777, but cancer cell resistance to these drugs has not been studied in detail.",

author = "Olesen, {Uffe H} and Petersen, {Jakob Geert} and Antje Garten and Wieland Kiess and Jun Yoshino and Shin-Ichiro Imai and Christensen, {Mette K} and Peter Fristrup and Thougaard, {Annemette V} and Fredrik Bj{\"o}rkling and Jensen, {Peter Boie Lind} and Nielsen, {S{\o}ren J} and Maxwell Sehested",

year = "2010",

month = jan,

day = "1",

doi = "10.1186/1471-2407-10-677",

language = "English",

volume = "10",

pages = "677",

journal = "B M C Cancer",

issn = "1471-2407",

publisher = "BioMed Central Ltd",

}

TY - JOUR

T1 - Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase

AU - Olesen, Uffe H

AU - Petersen, Jakob Geert

AU - Garten, Antje

AU - Kiess, Wieland

AU - Yoshino, Jun

AU - Imai, Shin-Ichiro

AU - Christensen, Mette K

AU - Fristrup, Peter

AU - Thougaard, Annemette V

AU - Björkling, Fredrik

AU - Jensen, Peter Boie Lind

AU - Nielsen, Søren J

AU - Sehested, Maxwell

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Inhibitors of nicotinamide phosphoribosyltransferase (NAMPT) are promising cancer drugs currently in clinical trials in oncology, including APO866, CHS-828 and the CHS-828 prodrug EB1627/GMX1777, but cancer cell resistance to these drugs has not been studied in detail.

AB - Inhibitors of nicotinamide phosphoribosyltransferase (NAMPT) are promising cancer drugs currently in clinical trials in oncology, including APO866, CHS-828 and the CHS-828 prodrug EB1627/GMX1777, but cancer cell resistance to these drugs has not been studied in detail.

U2 - 10.1186/1471-2407-10-677

DO - 10.1186/1471-2407-10-677

M3 - Journal article

C2 - 21144000

VL - 10

SP - 677

JO - B M C Cancer

JF - B M C Cancer

SN - 1471-2407

ER -

Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase

Abstract

Access to Document

Fingerprint

Cite this